New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

In Part Two, putting theory into practice is addressed.

The joint information sharing agreement between the medicines regulatory authority and reimbursement agency was first ...